01 February 2006
Venlafaxine HCl in the treatment of painful peripheral uremic neuropathy: a case report
Ali Kemal Kadiroglu , Dede Sit , Hasan Kayabasi , Emin Yilmaz , Bunyamin IsikogluCase Rep Clin Pract Rev 2006; 7:159-161 :: ID: 452156
Abstract
Background: It is well known that uremia may lead symmetric sensorimotor polyneuropathy that tends to
affect the lower limbs compared to upper limbs. It typically involves the legs than the arms. Clinical manifestations include paresthesia, painful dysesthesia, weakness in the legs and arms.
The traditional tricyclic antidepressants (TCA) are commonly used in the treatment of painful peripheral polyneuropathy. Venlafaxine is a serotonin noradrenaline reuptake inhibitor that may have analgesic effect on painful peripheral polyneuropathy.
Case Report: Venlafaxine extended release capsule (Effexor 75mg XR, Wyeth) was administered to a 49 years old female patient who has been under hemodialysis therapy for 7 years. She complained of
bilateral numbness, pain, pin-pricking and burning in her feet that increasing in the evening. She was also suffered from insomnia for two months. The patient’s symptoms were resolved in two weeks after beginning to the therapy but the intensity of pain continued minimaly and the patients demonstrated effective improvements at her insomnia in this period. Venlafaxine was well tolerated and there were no side effects such as nasuea, elevated blood pressure and
dizziness.
Conclusions: Venlafaxine relieved the symptoms of the uremic polyneuropathy and it was effective in
insomnia.
Keywords: Venlafaxine HCl, painful peripheral polyneuropathy, Uremia
366
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948268
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948283
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947725
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947694
Most Viewed Current Articles
21 Jun 2024 : Case report
102,058
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
54,550
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
38,308
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
07 Jul 2023 : Case report
26,047
DOI :10.12659/AJCR.940200
Am J Case Rep 2023; 24:e940200